-
2024-518527-29-00
4
2022-05-24
Polycystic ovary syndrome (PCOS)
-
2023-506278-10-00
5
2022-04-22
Eosinophilic esophagitis
-
2024-514336-24-00
5
2022-03-24
Familial Chylomicronemia Syndrome (FCS)
-
2023-506074-12-00
5
2022-03-22
Metastatic Non-Small Cell Lung Cancer
-
2023-507688-20-00
5
2021-12-03
Participants with completely resected Stage III or Stage IV melanoma
-
2023-509782-20-00
4
2021-11-11
Diffuse Cutaneous Systemic Sclerosis
-
2022-500881-80-00
5
2021-10-29
Chronic Heart Failure With Reduced Ejection Fraction
-
2024-511381-36-00
5
2021-10-13
Chronic Myelogenous Leukemia in chronic phase (CML-CP)
-
2024-510744-31-00
5
2021-10-06
Giant cell arteritis (GCA)
-
2024-512880-30-00
5
2021-08-27
Neovascular Age-related Macular Degeneration (wet AMD)
-
2024-513569-38-00
10
2021-07-09
Crohn's Disease
-
2023-508259-38-00
5
2021-04-29
Adult patients with relapsed or primary refractory DLBCL
-
2023-507846-96-00
5
2020-06-19
Type 2 Diabetes Mellitus
-
2022-501972-25-00
5
2020-04-06
Locally Advanced Cervical Cancer
-
2023-506715-18-00
5
2019-12-04
colon cancer stage II, rectal cancer stage II
-
2023-509134-19-00
5
2019-10-23
Myopia
-
2023-505614-17-00
5
2019-09-20
Participants with advanced or recurrent endometrial carcinoma
-
2023-503956-29-00
5
2019-08-26
Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient
M
-
2024-511972-33-00
5
2019-08-05
Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
-
2023-509296-16-00
4
2019-06-17
Moderate to severe hidradenitis suppurativa
-
2024-512821-10-00
4
2019-06-17
Early invasive triple negative breast cancer with positive HRD status
-
2023-503898-38-00
5
2019-05-24
Atopic Dermatitis
-
2022-502747-35-00
5
2019-02-18
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
-
2023-510200-42-00
5
2017-12-06
primary sclerosing cholangitis (PSC)